News
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
4h
Zacks.com on MSNPrecision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue EstimatesPrecision BioSciences (DTIL) delivered earnings and revenue surprises of -413.95% and 99.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock ...
DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — Precision BioSciences Inc. (DTIL) on Thursday reported a loss of $20.6 million in its first quarter. On a per-share basis, the Durham, North Carolina-based ...
Analysts estimate that Precision BioSciences will report an earnings per share (EPS) of $-2.42. Precision BioSciences bulls ...
Precision BioSciences (NASDAQ:DTIL) is scheduled to announce Q1 earnings results on Thursday, May 15th, before market open. The consensus EPS Estimate is -$2.42 (-242.4% Y/Y) and the consensus Revenue ...
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.35 per share a year ago. These ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
2d
Zacks Investment Research on MSNAkoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue EstimatesAkoya Biosciences (AKYA) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.35 per share a year ago. These figures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results